Acalabrutinib (Calquence®): First Global Approval – Downstream approach dams the ability for tumour-survival in patients with mantle cell lymphoma

Acalabrutinib (Calquence®): First Global Approval – Downstream approach dams the ability for tumour-survival in patients with mantle cell lymphoma

The recent first global approval of acalabrutinib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2].

In October 2017, acalabrutinib (Calquence®), developed by Acerta Pharma, received its first global approval in the US for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Continue reading “Acalabrutinib (Calquence®): First Global Approval – Downstream approach dams the ability for tumour-survival in patients with mantle cell lymphoma”

Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM

Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM

The recent first (double) global approval of midostaurin has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM”